دانلود مقالات ISI درباره Nivolumab + ترجمه فارسی

ReviewImmunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges

Keywords: Non-small-cell lung cancer; Immune checkpoint inhibitor; Pembrolizumab; Nivolumab; Atezolizumab; PDL1; PD1;

دانلود رایگان متن کامل مقاله ISI 8 صفحه سال انتشار : 2017 سفارش ترجمه

Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer

Keywords: Circulating tumour DNA; Immunotherapy; Nivolumab; Lung cancer; PD-1;

دانلود رایگان متن کامل مقاله ISI 9 صفحه سال انتشار : 2017 سفارش ترجمه

Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease

Keywords: ARGX-110; Brentuximab vedotin; Bortezomib; Copanlisib; cutaneous T-cell lymphoma; Forodesine; Gemcitabine; HDAC inhibitors; Ipilimumab; IPH4102; Mogamulizumab; Nivolumab; NM-IL-12; Panobinostat; Pegylated liposomal doxorubicin; Pentostatin; Pralatrexate;

دانلود رایگان متن کامل مقاله ISI 9 صفحه سال انتشار : 2017 سفارش ترجمه

Original ResearchProgrammed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity

Keywords: Metastatic melanoma; Nivolumab; Pembrolizumab; PD-1 inhibitor; Autoimmunity; Ipilimumab; Immune-related adverse events;

دانلود رایگان متن کامل مقاله ISI 9 صفحه سال انتشار : 2017 سفارش ترجمه

Original ResearchIpilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

Keywords: Nivolumab; Pembrolizumab; Treatment failure; Efficacy; Ipilimumab; Ipilimumab and nivolumab; Melanoma; Disease progression; Anti-PD-1;

دانلود رایگان متن کامل مقاله ISI 9 صفحه سال انتشار : 2017 سفارش ترجمه

ReviewMyasthenia gravis: An emerging toxicity of immune checkpoint inhibitors

Keywords: Immune checkpoint inhibitors; Myasthenia gravis; Immune-related adverse events; Pembrolizumab; Nivolumab; Ipilimumab; PD-1; CTLA-4; Autoimmunity;

دانلود رایگان متن کامل مقاله ISI 9 صفحه سال انتشار : 2017 سفارش ترجمه

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025

Keywords: Advanced renal cell carcinoma; Everolimus; Nivolumab; Phase 3; Treatment beyond progression;

دانلود رایگان متن کامل مقاله ISI 9 صفحه سال انتشار : 2017 سفارش ترجمه

Anti-PD1/PDL1 induced psoriasis

Keywords: Anti-PD1; Psoriasis; Nivolumab; Pembrolizumab; Durvalumab;

دانلود رایگان متن کامل مقاله ISI 9 صفحه سال انتشار : 2017 سفارش ترجمه

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Keywords: Everolimus; Immune checkpoint inhibitor; Nivolumab; Phase 3; Renal cell carcinoma;

دانلود رایگان متن کامل مقاله ISI 10 صفحه سال انتشار : 2017 سفارش ترجمه

Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials

Keywords: Pembrolizumab; Nivolumab; Non-small cell lung cancer; Adverse effects; Pneumonitis;

دانلود رایگان متن کامل مقاله ISI 10 صفحه سال انتشار : 2017 سفارش ترجمه

Original ResearchPrognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Keywords: Ipilimumab; Pembrolizumab; Nivolumab; Immune checkpoint blockade; Uveal melanoma; Biomarker;

دانلود رایگان متن کامل مقاله ISI 10 صفحه سال انتشار : 2017 سفارش ترجمه

Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable

Keywords: Pembrolizumab; Nivolumab; Me-too drugs; Drug manufacturing;

دانلود رایگان متن کامل مقاله ISI 12 صفحه سال انتشار : 2017 سفارش ترجمه

Health-related quality of life results from the phase III CheckMate 067 study

Keywords: Health-related quality of life; Checkpoint inhibitors; Advanced melanoma; Nivolumab; Ipilimumab;

دانلود رایگان متن کامل مقاله ISI 12 صفحه سال انتشار : 2017 سفارش ترجمه

Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma

Keywords: NSCLC; Nivolumab; EBUS; Adenocarcinoma;

دانلود رایگان متن کامل مقاله ISI 14 صفحه سال انتشار : 2017 سفارش ترجمه

Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab

Keywords: CT; computer tomography; PET; positron emission tomography; RS3PE; remitting seronegative symetrical synovitis with pitting edema; PD-1; programmed cell-death-1; PDL-1; programmed cell-death ligand-1; CRP; C-reactive protein; CCP; cyclic citrullinated pep

دانلود رایگان متن کامل مقاله ISI 19 صفحه سال انتشار : 2017 سفارش ترجمه

Cutting the Brakes: Immunotherapy With PD-1 Inhibitors

Keywords: Immune checkpoint; Melanoma; Nivolumab; PD-L1; Pembrolizumab;

دانلود رایگان متن کامل مقاله ISI 28 صفحه سال انتشار : 2017 سفارش ترجمه

Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review

Keywords: Nivolumab; Pembrolizumab; PD-1; Anti-PD-1; Melanoma; Lung cancer;

دانلود رایگان متن کامل مقاله ISI 28 صفحه سال انتشار : 2017 سفارش ترجمه

Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review

Keywords: Uveal melanoma; CTLA-4; Ipilimumab; Immune checkpoint blockade; Pembrolizumab; Nivolumab;

دانلود رایگان متن کامل مقاله ISI 29 صفحه سال انتشار : 2017 سفارش ترجمه

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions

Keywords: Immunotherapy; PD-1, CTLA-4; Nivolumab; Ipilimumab; Adverse drug reaction;

دانلود رایگان متن کامل مقاله ISI 35 صفحه سال انتشار : 2017 سفارش ترجمه

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study

Keywords: Immune checkpoint inhibitor; Immune-related adverse event; Nivolumab; Non-small cell lung cancer; Programmed cell death ligand 1;

دانلود رایگان متن کامل مقاله ISI 39 صفحه سال انتشار : 2017 سفارش ترجمه

Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases

Keywords: CNS; central nervous system; K-RAS; Kirsten rat sarcoma; mRECIST; modified Response Evaluation Criteria in Solid Tumors; MRI; magnetic resonance imaging; NSCLC; non-small cell lung cancer; pts; patients; PET-CT; positron emission tomography-computer tomog

دانلود رایگان متن کامل مقاله ISI 4 صفحه سال انتشار : 2016 سفارش ترجمه

Le diabète fulminant, un effet secondaire grave des anticorps anti-PD1 : à propos de quatre cas survenus en cours de traitement pour mélanome

Keywords: Diabète de type 1 fulminant; cétose; anticorps anti-PD-1; effets secondaires; toxicité; pembrolizumab; nivolumab; évènements adverse immuno-dépendants; Fulminant type 1 diabetes; ketosis; anti-PD-1 antibodies; side-effects; toxicity; pembrolizumab;

دانلود رایگان متن کامل مقاله ISI 4 صفحه سال انتشار : 2016 سفارش ترجمه

Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression

Keywords: Pseudoprogression; Nivolumab; Non-small cell lung cancer; Adenocarcinoma;

دانلود رایگان متن کامل مقاله ISI 5 صفحه سال انتشار : 2016 سفارش ترجمه

What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma

Keywords: Checkpoint inhibitors; HL; Nivolumab; Programmed death inhibitor; Transplant;

دانلود رایگان متن کامل مقاله ISI 5 صفحه سال انتشار : 2016 سفارش ترجمه

Place des anti-PD1 dans la prise en charge des mélanomes cutanés

Keywords: Mélanome métastatique; Pembrolizumab; Nivolumab; Immunothérapie; Anti-PD1; Mestastatic melanoma; Pembrolizumab; Nivolumab; Immunotherapy; Anti-PD1;

دانلود رایگان متن کامل مقاله ISI 8 صفحه سال انتشار : 2016 سفارش ترجمه

Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis

Keywords: nSMOL; nano-surface and molecular-orientation limited proteolysis; Nivolumab; Immune checkpoint inhibitor; Monoclonal antibody; nSMOL; Bioanalysis; LCMS;

دانلود رایگان متن کامل مقاله ISI 8 صفحه سال انتشار : 2016 سفارش ترجمه

PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis

Keywords: PD-L1; PD-1; Nivolumab; Pembrolizumab; Rectal; Cancer; Adenocarcinoma; Radiation; Radiochemotherapy; Radiotherapy;

دانلود رایگان متن کامل مقاله ISI 9 صفحه سال انتشار : 2016 سفارش ترجمه

Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis

Keywords: NSCLC; PD-1; PD-L1; Nivolumab; Pembrolizumab;

دانلود رایگان متن کامل مقاله ISI 11 صفحه سال انتشار : 2016 سفارش ترجمه

Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies

Keywords: PD-1; PD-L1; PD-L2; Lymphoid malignancies; Pidilizumab; Nivolumab; Pembrolizumab

دانلود رایگان متن کامل مقاله ISI 14 صفحه سال انتشار : 2016 سفارش ترجمه

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

Keywords: Adverse events; Immune-checkpoint; Immunotherapy; Nivolumab; PD-1; Pembrolizumab; Programmed death-1; Pruritus; Rash; Vitiligo;

دانلود رایگان متن کامل مقاله ISI 14 صفحه سال انتشار : 2016 سفارش ترجمه

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

Keywords: Anti-PD-1; Side-effect; Toxicity; Pembrolizumab; Nivolumab; Checkpoint inhibitors; Tolerability; Immune-related; Adverse event;

دانلود رایگان متن کامل مقاله ISI 16 صفحه سال انتشار : 2016 سفارش ترجمه

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

Keywords: Anti-PD-1; Side-effect; Toxicity; Pembrolizumab; Nivolumab; Checkpoint inhibitors; Tolerability; Immune-related; Adverse event;

دانلود رایگان متن کامل مقاله ISI 20 صفحه سال انتشار : 2016 سفارش ترجمه

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing

Keywords: Lung cancer; Nivolumab; Docetaxel; Cost-effectiveness; QALY; ICER;

دانلود رایگان متن کامل مقاله ISI 27 صفحه سال انتشار : 2016 سفارش ترجمه

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

Keywords: Immunotherapy; PD-1; Nivolumab; Pembrolizumab; Adverse drug reaction; Immune-related adverse events;

دانلود رایگان متن کامل مقاله ISI 33 صفحه سال انتشار : 2016 سفارش ترجمه

Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer - Review of current data

Keywords: Nivolumab; Ipilimumab; Head and neck cancer; PD-1; CTLA-4; Immunotherapy;

دانلود رایگان متن کامل مقاله ISI 4 صفحه سال انتشار : 2015 سفارش ترجمه

Rola przeciwciał monoklonalnych anty CD30 i anty PD-1 w terapii nawrotowego/opornego chłoniaka Hodgkina

Keywords: chłoniak Hodgkina; brentuksimab vedotin; nivolumab; pembrolizumabHodgkin lymphoma; Brentuximab vedotin; Nivolumab; Pembrolizumab

دانلود رایگان متن کامل مقاله ISI 5 صفحه سال انتشار : 2015 سفارش ترجمه

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

Keywords: melanoma; MPDL3280A; nivolumab; PD-1; PD-L1; pembrolizumab; pidilizumab; programmed cell death 1;

دانلود رایگان متن کامل مقاله ISI 19 صفحه سال انتشار : 2015 سفارش ترجمه